Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2008-01-03
2010-12-28
Bristol, Lynn (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S178100, C430S391000
Reexamination Certificate
active
07858088
ABSTRACT:
The present invention relates to a method for stabilizing chimeric immunoglobulins or immunoglobulin fragments. Furthermore, the invention also provides a stabilized anti-EGP-2 scFv fragment.
REFERENCES:
patent: 7341722 (2008-03-01), Pluckthun et al.
patent: 2005/0136049 (2005-06-01), Ledbetter et al.
patent: 2004096271 (2004-11-01), None
Gibson et al., Proteins 3:155-60, 1988.
Knappik et al., Protein Engineering 8:81-89, 1995.
Saul et al ., J Mol. Biol 230:15-20, 1993.
Al-Lazikani et al., “Standard Conformations for the Canonical Structures of Immunoglobulins”, J. Mol. Biol., 1997, p. 927-948, vol. 273, Academic Press Limited.
Bothmann et al., “Selection for a periplasmic factor improving Phage display and functional periplasmic expression”, Nature Biotechnology, Apr. 1998, pp. 376-380, vol. 16.
Carter et al., “Engineering antibodies for imaging and therapy”, Protein Engineering, pp. 449-454, vol. 8 Current Op. Biotech (1997).
Carter et al., “Humanization of an anti-p185.sup.HER2 antibody for human cancer therpay”, Proc. Natl. Acad. Sci. USA, May 1992, pp. 4285-4289, vol. 89, Immunology.
Eigenbrot et al., “X-ray Structures of the Antigen binding Domains from Three Variants of Humanized anti-185.sup. HER2 Antibody 4D5 and Comparison with Molecular Modeling”, J. Mol. Biol. 1993, pp. 969-995, vol. 229, Academic Press Limited.
Glockshuber et al., “A Comparison of Strategies to Stabilize Immunoglobulin F.sub.v-Fragments”, Biochemistry, 1990, pp. 1362-1367, vol. 29, No. 6, American Chemical Society.
Helfrich et al., “Construction and Characterization of a Bispecific Diabody for Retargeting T Cells to Human Carcinomas”, Int. J. Cancer, 1998, pp. 232-239, vol. 26, Wiley-Liss, Inc.
Jung et al, “Improving in vivo folding and stability of a single-chain Fv antibody fragment by loop grafting”, Protein Engineering, 1997, pp. 959-966, vol. 10, No. 8, Oxford University Press.
Knappik et al., “Engineered turns of a recombinant antibody improve its in vivo folding”, Protein Engineering, Jan. 1995, pp. 81-89, No. 1.
Langedijk et al., “The Nature of Antibody Heavy Chain Residue H6 Strongly Influences of a V.sub.H Domain Lacking the Disulfide Bridge”, J. Mol. Biol., 1998, pp. 95-110, vol. 283, Academic Press.
Pluckthun et al., “New protein engineering approaches to multivalent and bispecific antibody fragments”, Immunotechnology, 1997, pp. 83-105, vol. 3, Elsevier.
Proba et al., “Antibody scFv Fragments Without Disulfide Bonds Made by Molecular Evolution”, J. Mol. Biol., 1998, pp. 245-253, vol. 275, Academic Press Limited.
Saul et al., “Structural Patterns at Residue Positions 9, 18, 67 and 82 in the V.sub.H Framework Regions of Human and Murine Immunoglobulins”, J. Mol. Biol., 1993, pp. 15-20, vol. 230, Academic Press Limited.
Worn et al., “An intrinsically stable antibody scFv fragment can tolerate the loss of both disulfide bonds and fold correctly”, FEBS Letters, 1998, pp. 357-361, vol. 427, Federation of European Biochemical Societies.
Stratagen Catalog (1998) (pp. 1-2).
Dermer Biotechnology 12: 320, 1994.
Gura et al (Science vol. 278 Nov. 1997 1041-1042).
Seaver (1994; Genetic Engineering vol. 14(14):pp. 10 and 21.
Willuda J., et al. “Rational engineering for high stability is required for tumor targeting of a high-affinity scFv fragment specific for the panepithelial glycoprotein egp-2.” Proceedings of the American Association for Cancer Research Annual Meeting (Mar. 1999), vol. 40, O. 354, Abst. 2343, Meeting Info,: 90th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, USA, Apr. 10-14, 1999.
Krebber, A., et al. “Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. ”J. Immunol. Meth., 201(1): 35-55 (Feb. 14, 1997).
Jung, S., et al. “Improving in vico folding and stability of a single-chain Fv antibody fragment by loop grafting.” Protein Engineering, 10(8): 959-66 (Aug. 1997).
Proba, K., et al. “Antibody scFv fragments without disulfide bonds made by molecular evolution.” J. Molec. Biol., 275 (2): 245-53 (Jan. 16, 1998).
Willuda J., et al. “High thermal stability is essential for tumor targeting of antibody fragments: Engineering of a humanized anti-epithelial glycoprotein-2 (Epithelial cell adhesion molecule) single-chain Fv fragment.” Cancer Research, 59(22): 5758-5767 (Nov. 15, 1999).
Waibel, R., et al. “Stable one-step technetium -99m labeling of His-tagged recombinant proteins with a novel Tc(I)- carbonyl complex.” Nature Biotechnology 17(9): 897-901 (Sep. 1999).
Honegger Annemarie
Plückthun Andreas
Willuda Jörg
Bristol Lynn
Dann, Dorfman, Herrell & Skill
Rigaut Kathleen D.
University of Zurich
LandOfFree
Method for the stabilization of chimeric immunoglobulins or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the stabilization of chimeric immunoglobulins or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the stabilization of chimeric immunoglobulins or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4163347